Association of a common TLR-6 polymorphism with coronary artery disease - implications for healthy ageing?

Immunity and Ageing

Volumn 10, Issue 1, 2013, Pages

  Hamann, Lutz ^a   Koch, Alexander ^b   Sur, Saubashya ^a   Hoefer, Nadja ^a   Glaeser, Christiane ^c   Schulz, Susanne ^c   Gross, Michael ^a   Franke, Andre ^d   Nöthlings, Ute ^d,e   Zacharowski, Kai ^b   Schumann, Ralf R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Coronary artery disease (CAD); Gene polymorphism; Innate immunity; Restenosis; Toll like receptor (TLR) 6

Indexed keywords

TOLL LIKE RECEPTOR 6;

ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84887033738     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-10-43     Document Type: Article

References (51)

1. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004, 39(5):687-699. 10.1016/j.exger.2004.01.009, 15130663.
2. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.
3. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, Caruso C. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005, 2:8. 10.1186/1742-4933-2-8, 1166571, 15904534.
4. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007, 128(1):83-91. 10.1016/j.mad.2006.11.015, 17118425.
5. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Measuring the global burden of disease and risk factors: 1990-2001. Global Burden of Disease and Risk Factors. Chapter 1 2006, Washington (DC): World Bank, Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL.
6. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74(2):213-220. 10.1253/circj.CJ-09-0706, 20065609.
7. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007, 100(5A):3K-9K.
8. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffrè PA, Romeo F, Crea F. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 2002, 40(11):1935-1942. 10.1016/S0735-1097(02)02562-7, 12475452.
9. Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, Fram DB, Wu AH, Waters DD. Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 1997, 80(11):1476-1478. 10.1016/S0002-9149(97)00726-1, 9399726.
10. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007, 195(2):374-378. 10.1016/j.atherosclerosis.2006.10.026, 17126343.
11. Hold LM, Teupser D. From genotype to phenotype in human atherosclerosis - recent findings. Curr Opin Lipidol 2013, 24(5):410-418.
12. Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005, 6(3):S61-S73.
13. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753. 10.1038/nature08494, 2831613, 19812666.
14. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34(5):637-650. 10.1016/j.immuni.2011.05.006, 21616434.
15. Schroder NW, Schumann RR. Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005, 5(3):156-164.
16. Michelsen K, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004, 101(29):10679-10684. 10.1073/pnas.0403249101, 489994, 15249654.
17. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209(2):314-320. 10.1016/j.atherosclerosis.2009.09.075, 19900676.
18. Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLoS One 2008, 3(9):e3204. 10.1371/journal.pone.0003204, 2527517, 18787704.
19. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest 2005, 115(11):3149-3156. 10.1172/JCI25482, 1242192, 16211093.
20. Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther 2010, 8(11):1619-1635. 10.1586/erc.10.149, 21090937.
21. Curtiss LK, Tobias PS. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res 2009, 50(Suppl):S340-S345. 2674724, 18980945.
22. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007, 4(8):444-454. 10.1038/ncpcardio0938, 17653117.
23. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010, 11(2):155-161. 10.1038/ni.1836, 2809046, 20037584.
24. Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012, 122(2):558-568. 10.1172/JCI58969, 3266787, 22214850.
25. Sales ML, Schreiber R, Ferreira-Sae MC, Fernandes MN, Piveta CS, Cipolli JA, Cardoso CC, Matos-Souza JR, Geloneze B, Franchini KG, Nadruz W. Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens 2010, 23(6):649-654. 10.1038/ajh.2010.24, 20224557.
26. Shey MS, Randhawa AK, Bowmaker M, Smith E, Scriba TJ, de Kock M, Mahomed H, Hussey G, Hawn TR, Hanekom WA. Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion. Genes Immun 2010, 11(7):561-572. 10.1038/gene.2010.14, 3518443, 20445564.
27. Hamann L, Gomma A, Schroder NW, Stamme C, Glaeser C, Schulz S, Gross M, Anker SD, Fox K, Schumann RR. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005, 83(6):478-485. 10.1007/s00109-005-0643-7, 15875151.
28. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352(16):1685-1695. 10.1056/NEJMra043430, 15843671.
29. Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, Shimokado K, Sacks FM, Yoshida M. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008, 103(12):1402-1409. 10.1161/CIRCRESAHA.108.178426, 2994199, 18974386.
30. Abe Y, Kawakami A, Osaka M, Uematsu S, Akira S, Shimokado K, Sacks FM, Yoshida M. Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via toll-like receptor 2 pathway in mouse adipocytes. Arterioscler Thromb Vasc Biol 2010, 30(11):2242-2248. 10.1161/ATVBAHA.110.210427, 3203842, 20829510.
31. Brull DJ, Leeson CP, Montgomery HE, Mullen M, de Divitiis M, Humphries SE, Deanfield JE. The effect of the Interleukin-6-174G > C promoter gene polymorphism on endothelial function in healthy volunteers. Eur J Clin Invest 2002, 32(3):153-157. 10.1046/j.1365-2362.2002.00966.x, 11895465.
32. Zhu Y, Hojo Y, Ikeda U, Takahashi M, Shimada K. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol 2000, 36(2):152-161. 10.1097/00005344-200008000-00003, 10942155.
33. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom WA, Hawn TR, South African Tuberculosis Vaccine Initiative Team Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS Pathog 2011, 7(8):e1002174. 10.1371/journal.ppat.1002174, 3154845, 21852947, South African Tuberculosis Vaccine Initiative Team.
34. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85(8):e17-e24. 10.1161/01.RES.85.8.e17, 10521249.
35. Cartwright N, McMaster SK, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, Quesniaux VF, Evans TW, Mitchell JA. Elucidation of toll-like receptor and adapter protein signaling in vascular dysfunction induced by gram-positive staphylococcus aureus or gram-negative escherichia coli. Shock 2007, 27(1):40-47. 10.1097/01.shk.0000235127.59492.db, 17172979.
36. Curtiss LK, Black AS, Bonnet DJ, Tobias PS. Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists. J Lipid Res 2012, 53(10):2126-2132. 10.1194/jlr.M028431, 3435545, 22822027.
37. Navi A, Patel H, Shaw S, Baker D, Tsui J. Therapeutic role of toll-like receptor modification in cardiovascular dysfunction. Vascul Pharmacol 2013, 58(3):231-239. 10.1016/j.vph.2012.10.001, 23070056.
38. Laskowski RA, Luscombe NM, Swindells MB, Thornton JM. Protein clefts in molecular recognition and function. Protein Sci 1996, 5(12):2438-2452. 2143314, 8976552.
39. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, Emerson A, Fanelli F, Gohlke H, Kuhn LA, Morris GM, Orozco M, Pertinhez TA, Rizzi M, Sotriffer CA. Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 2008, 51(20):6237-6255. 10.1021/jm800562d, 2701403, 18785728.
40. Depp CA, Jeste DV. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am J Geriatr Psychiatry 2006, 14(1):6-20. 10.1097/01.JGP.0000192501.03069.bc, 16407577.
41. Melzer D, Hurst AJ, Frayling T. Genetic variation and human aging: progress and prospects. J Gerontol A Biol Sci Med Sci 2007, 62(3):301-307. 10.1093/gerona/62.3.301, 17389728.
42. Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW, Melista E, Andersen S, Dworkis DA, Wilk JB, Myers RH, Steinberg MH, Montano M, Baldwin CT, Hoh J, Perls TT. Genetic signatures of exceptional longevity in humans. PLoS One 2012, 7(1):e29848. 10.1371/journal.pone.0029848, 3261167, 22279548.
43. Koch A, Hamann L, Schott M, Boehm O, Grotemeyer D, Kurt M, Schwenke C, Schumann RR, Bornstein SR, Zacharowski K. Genetic variation of TLR4 influences immunoendocrine stress response: an observational study in cardiac surgical patients. Crit Care 2011, 15(2):R109. 10.1186/cc10130, 3219387, 21466684.
44. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993, 234(3):779-815. 10.1006/jmbi.1993.1626, 8254673.
45. Kaplan W, Littlejohn TG. Swiss-PDB viewer (deep view). Brief Bioinform 2001, 2(2):195-197. 10.1093/bib/2.2.195, 11465736.
46. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007, 35(Web Server issue):W407-W410. 1933241, 17517781.
47. Laskowski RA, Moss DS, Thornton JM. Main-chain bond lengths and bond angles in protein structures. J Mol Biol 1993, 231(4):1049-1067. 10.1006/jmbi.1993.1351, 8515464.
48. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 2006, 34(Web Server issue):W116-W118. 1538779, 16844972.
49. Laskowski RA, Watson JD, Thornton JM. ProFunc: a server for predicting protein function from 3D structure. Nucleic Acids Res 2005, 33(Web Server issue):W89-W93. 1160175, 15980588.
50. Keating KS, Flores SC, Gerstein MB, Kuhn LA. StoneHinge: hinge prediction by network analysis of individual protein structures. Protein Sci 2009, 18(2):359-371. 10.1002/pro.38, 2708048, 19180449.
51. Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics 2006, 22(22):2729-2734. 10.1093/bioinformatics/btl423, 16895930.